LAUSR

Nipple‐sparing mastectomy is an alternative to skin‐sparing mastectomy in select patients. Increasing evidence supports its use in the setting of breast cancer, however concerns still exist regarding oncological safety. The aim of this systematic review was to evaluate long‐term oncological outcomes of patients who underwent nipple‐sparing mastectomy for breast cancer. A systematic review of the literature was performed to evaluate oncological outcomes in patients with breast cancer who underwent nipple‐sparing mastectomy. Five major databases (PubMed, Embase, Scopus, Web of Science and Cochrane) were searched. The review included all original articles published in English reporting long‐term oncological outcomes. 2334 studies were identified. After applying inclusion and exclusion criteria, 17 retrospective studies involving 7107 patients were included. The indication for nipple‐sparing mastectomy was invasive carcinoma in 6069 patients (85.4%) and in situ disease in 1038 (14.6%). Median follow up was 48 months (range 25–94). The weighted mean rates of local recurrence and recurrence involving the nipple‐areola complex were 5.4% (0.9–11.9) and 1.3% (0–4.9), respectively. The weighted mean distant failure rate was 4.8% (1.5–23.0). Therapeutic nipple‐sparing mastectomy is oncologically safe in select patients with breast cancer.